Immunogenicity of a recombinant lentiviral vector carrying human telomerase tumor antigen in HLA-B*0702 transgenic mice

Vaccine
Sylvie RusakiewiczOlivier Adotevi

Abstract

Over expression of telomerase represents a hallmark of cancer cells and the induction of T cell immunity against this universal tumor antigen have gained promising interest for anticancer immunotherapy. In this study we evaluated a recombinant lentiviral vector expressing the human telomerase reverse transcriptase (lv-hTERT) vaccination in the humanized HLA-B*0702 transgenic (HLA-B7 Tg) mice. A single lv-hTERT vector immunization induces potent and broad HLA-B7-restricted CTL responses against hTERT. Unlike conventional hTERT peptide or DNA immunization, the lv-hTERT vector triggers high and sustained IFN-gamma producing CD8(+) T cell responses in HLA-B7 Tg mice. The avidity and in vivo cytotoxicity of CD8(+) T cells were stronger in lv-hTERT vector-immunized mice than in hTERT peptide or DNA vaccinated groups. The study also showed that the use of prime-boost vaccination drastically improved the magnitude and strength of lentivector-primed CD8(+) T cells. Our data indicated that lentiviral delivery of hTERT is suitable for enhancing cellular immunity against hTERT and offers a promising alternative for telomerase-based cancer vaccine.

References

Apr 1, 1997·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J W Shay, S Bacchetti
Nov 24, 1999·Immunological Reviews·J SchneiderA V Hill
May 11, 2002·Nature Reviews. Immunology·Susan M KaechRaft Ahmed
Dec 13, 2002·Vaccine·Pedro RomeroJean-Charles Cerottini
Mar 11, 2003·Proceedings of the National Academy of Sciences of the United States of America·Jan C SchmollingerGlenn Dranoff
Mar 30, 2004·Current HIV Research·James T SnyderIgor M Belyakov
Jan 21, 2006·Cancer Research·Laurence ChapatteFrédéric Lévy
May 19, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Olivier AdotéviPierre Langlade-Demoyen
Nov 2, 2006·International Immunology·Xochitl Cortez-GonzalezMaurizio Zanetti
Feb 28, 2007·Journal of Translational Medicine·Xochtil Cortez-Gonzalez, Maurizio Zanetti
Jul 3, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Irini BolonakiDimitris Mavroudis
Jan 26, 2008·Nature Reviews. Cancer·Jason RiceFreda K Stevenson
Feb 8, 2008·Nature Reviews. Cancer·Calvin B Harley
Apr 2, 2008·Expert Review of Vaccines·Yukai HeLouis D Falo
Sep 5, 2008·Expert Review of Vaccines·Gregory L Beatty, Robert H Vonderheide
Aug 20, 2009·Current Molecular Medicine·Caroline J VoskensDuane A Sewell
Nov 6, 2009·Carcinogenesis·Steven E Artandi, Ronald A DePinho

❮ Previous
Next ❯

Citations

Aug 25, 2012·Cancer Biotherapy & Radiopharmaceuticals·Guichun HuangLongbang Chen
May 7, 2015·Cancer Immunology, Immunotherapy : CII·Maria TagliamonteLuigi Buonaguro
Nov 20, 2015·Journal of Immunology Research·Cleo Goyvaerts, Karine Breckpot
Feb 13, 2014·Oncotarget·Cleo GoyvaertsKarine Breckpot
Oct 4, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Magalie DossetOlivier Adotévi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antigenic Modulation

Antigenic modulation occurs when an antibody cross-links antigens on a cell surface, causing the antigens to become internalized. This can lead to therapeutic failure of monoclonal antibodies as the expression of the antigen becomes decreased on target cells. Find the latest research on antigenic modulation here.